• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: KINETIC CONCEPTS, INC. V.A.C.® DRAPE; OMP

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

KINETIC CONCEPTS, INC. V.A.C.® DRAPE; OMP Back to Search Results
Model Number VACDSP
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Fungal Infection (2419)
Event Date 09/27/2023
Event Type  Injury  
Manufacturer Narrative
Based on the information provided, it cannot be determined that the alleged fungal infection is related to the v.A.C.® drape.Multiple unsuccessful attempts were made for additional clinical information from the healthcare provider.A device evaluation and a device history record review could not be performed.Device labeling, available in print and online, states: warning: never leave a v.A.C.® dressing in place without active v.A.C.® therapy for more than two hours.If therapy is off for more than two hours, remove the old dressing and irrigate the wound.Either apply a new v.A.C.® dressing from an unopened sterile package and restart v.A.C.® therapy; or apply an alternate dressing, such as a wet to moist gauze, as approved during times of extreme need, by treating physician.Dressing changes: wounds being treated with the v.A.C.® therapy system should be monitored on a regular basis.In a monitored, non-infected wound, v.A.C.® dressings should be changed every 48-72 hours, but no less than 3 times a week, with frequency adjusted by the clinician as appropriate.Infected wounds must be monitored often and very closely.For these wounds, dressings may need to be changed more often than 48-72 hours; the dressing changing intervals should be based on a continuing evaluation of the wound condition and the patient's clinical presentation, rather than a fixed schedule.Precautions: the v.A.C.® therapy system will not be effective in addressing complications associated with the following: ischemia to the incision or incision area.Untreated or inadequately treated infection.Inadequate hemostasis of the incision.Cellulitis of the incision area.Infected wounds: infected wounds should be monitored closely and may require more frequent dressing changes than noninfected wounds, dependent upon factors such as wound conditions, treatment goals.Refer to dressing application instructions (found in v.A.C.® dressing cartons) for details regarding dressing change frequency.As with any wound treatment, clinicians and patients / caregivers should frequently monitor the patient's wound, periwound tissue and exudate for signs of infection, worsening infection, or other complications.Some signs of infection are fever, tenderness, redness, swelling, itching, rash, increased warmth in the wound or periwound area, purulent discharge or strong odor.Infection can be serious, and can lead to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and/or fatal injury.Some signs or complications of systemic infection are nausea, vomiting, diarrhea, headache, dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation, high fever, refractory and/or orthostatic hypotension or erythroderma (a sunburn-like rash).If there are any signs of the onset of systemic infection or advancing infection at the wound site, contact the treating physician immediately to determine if v.A.C.® therapy should be discontinued.Disclaimer: this information is submitted pursuant to 21 cfr 803, in compliance with the medical device reporting requirement and should not be considered to be an admission that a kinetic concepts, inc.Product malfunctioned, is defective or has caused serious injury.
 
Event Description
On 02-oct-2023, the following information was provided to kci by the patient: on (b)(6) 2023, the activ.A.C.¿ ion progress¿ remote therapy monitoring system was removed allegedly due to skin irritation and fungal infection around the wound from the v.A.C.® drape.She has a history of reactions to tapes and adhesives.The patient is not sure if v.A.C.® therapy will be reapplied because the wound is looking good.On 24-oct-2023, the following information was provided to kci by the patient: the patient alleged the provider believed she was experiencing the beginning of a fungal infection due to moisture and skin irritation from the v.A.C.® drape.She stated that the provider prescribed her a topical ointment but could not provide the name of the medication.She confirmed her wound is improving.The v.A.C.® dressing type and lot number was not provided, and the product was not returned; therefore, a device evaluation and a device history record review could not be performed.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
V.A.C.® DRAPE
Type of Device
OMP
Manufacturer (Section D)
KINETIC CONCEPTS, INC.
san antonio TX 78249
Manufacturer Contact
steven jackson
6203 farinon drive
san antonio, TX 78249
2102556436
MDR Report Key18014016
MDR Text Key326638805
Report Number3009897021-2023-00069
Device Sequence Number1
Product Code OMP
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K133276
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer
Reporter Occupation Non-Healthcare Professional
Type of Report Initial
Report Date 10/26/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/26/2023
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberVACDSP
Device Lot NumberASKU
Was Device Available for Evaluation? No
Date Manufacturer Received10/02/2023
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age80 YR
Patient SexFemale
Patient Weight80 KG
-
-